FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and describes a combination of tetrahydrocannabinol (THC) and cannabidiole (CBD) cannabinoids in ratio 1:5 for preparing a drug applicable in treating glioma, wherein the cannabinoid concentration falls within the range of 5 to 100 mg of the total cannabinoid concentration, wherein treating glioma involves reducing the cell survival rate, suppressing the cell growth and reducing the tumour volume.
EFFECT: invention provides increasing the efficacy of cannabinoids in a combination of THC and CBD in treating glioma.
5 cl, 5 ex, 2 tbl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CANNABINOIDS IN COMBINATION WITH NON-CANNABINOID CHEMOTHERAPEUTIC AGENTS (FOR INSTANCE, SERMS OR ALKYLATING AGENTS) | 2009 |
|
RU2543034C2 |
| HERBAL EXTRACT OF HEMP WITH LOW CONTENT OF TETRAHYDROCANNABINOL (THC) FOR TREATMENT OF DISEASES | 2008 |
|
RU2599028C2 |
| COMPOSITIONS AND METHODS OF TREATING BRAIN CANCER | 2012 |
|
RU2705244C2 |
| AGENT POSSESSING CYTOTOXIC ACTIVITY WITH RESPECT TO U87MG GLIOMA CELL CULTURE | 2024 |
|
RU2839886C1 |
| METHOD FOR INHIBITING CEREBRAL TUMORS GROWTH DUE TO SELECTED ANTAGONISTS OF INTEGRINS | 2000 |
|
RU2255765C2 |
| CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
| METHOD FOR TREATING ENDOMETRIOSIS WITH PAIN SYNDROME AND PHARMACEUTICAL COMPOSITION FOR ITS IMPLEMENTATION | 2020 |
|
RU2745687C1 |
| CEREBRAL CANCER TREATMENT WITH ONCOLYTIC ADENOVIRUS | 2014 |
|
RU2689553C2 |
| APPLICATION OF ONE OR COMBINATION OF PHYTOCANNABINOIDS FOR TREATMENT OF EPILEPSY | 2010 |
|
RU2563143C2 |
| WAY OF ESTIMATION OF HIGH-QUALITY TYPICALNESS OF MONOECIOUS FORMS OF CULTURAL HEMP | 2006 |
|
RU2324335C1 |
